Impact of hepatitis C virus core mutations on the response to interferon-based treatment in chronic hepatitis C

Table 1 Demographic, clinical and virological characteristics of study patients n (%)

Characteristics	Total	IL28B CC	IL28B non-CC	P value
	n = 108	n = 19	n = 89
Age (yr), median	53.5 (22.0-68.3)	48.2 (22.1-66.4)	53.8 (22.1-68.3)	0.137
Female	64 (59.3)	8 (42.1)	56 (62.9)	0.094
Residence urban	78 (72.2)	17 (87.5)	61 (68.5)	0.090
Baseline ALT (mg/dL), median	76.5 (16-890)	103 (16-890)	74 (17-256)	0.031
Baseline HCV-RNA (log10IU/mL), median	6.1 (4.15-7.3)	6.2 (4.15-7.2)	6.1 (4.15-7.3)	0.333
Mild/moderate fibrosis	38 (58.5)	9 (69.23)	29 (55.8)	0.470
Absence of core mutations - DW	13 (12.0)	6 (31.6)	7 (7.9)	0.011
RVR (%)	14 (13.0)	7 (36.8)	7 (7.9)	0.003
EVR (%)	43 (39.8)	16 (84.2)	27 (30.3)	< 0.001
SVR (%)	42 (38.9)	17 (89.5)	25 (28.1)	< 0.001

HCV: Hepatitis C virus; DW: Double wild-type; SVR: Sustained virological response; EVR: Early virological response; RVR: Rapid virologic response.